The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Path: NSIP-fibrotic pattern
Publications
Upper lobe pulmonary fibrosis associated with high-dose chemotherapy containing BCNU for bone marrow transplantation.
Mayo Clinic proceedings 2003 May;78;630-4 — 2003 May — 630-4
Pulmonary fibrosis following low-dose 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) therapy.
Cancer 1980 Mar 15;45;1311-4 — 1980 Mar 15 — 1311-4
BCNU (1,3-bis-(2-chloroethyl)-1-nitrosurea) lung. Drug-induced pulmonary changes.
Cancer 1984 Aug 15;54;751-5 — 1984 Aug 15 — 751-5
Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood.
The New England journal of medicine 1990 Aug 09;323;378-82 — 1990 Aug 09 — 378-82
Late BCNU lung: a light and ultrastructural study on the delayed effect of BCNU on the lung parenchyma.
The Journal of pathology 1991 May;164;31-6 — 1991 May — 31-6
Fatal pulmonary fibrosis following 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) therapy.
Cancer 1978 Jul;42;74-6 — 1978 Jul — 74-6
Pulmonary toxicity of bischloronitrosourea: report of a case with transient response to corticosteroid therapy.
Cancer 1979 May;43;1607-12 — 1979 May — 1607-12